|
Researchers at Massachusetts Institute of Technology and Harvard Medical School have built targeted nanoparticles that can cling to artery walls and slowly release medicine, which could be an alternative to drug-eluting stents in some patients with cardiovascular disease, according to research published in the Jan. 18 issue of the Proceedings of the National Academy of Sciences.
Interventional product developer Invatec has received 510(k) clearance from the FDA to market its Mo.Ma Ultra proximal cerebral protection device for use during carotid artery stenting.
Abbott today settled all outstanding intellectual property litigation with Medtronic. Under the terms of the settlement, Medtronic will pay Abbott $400 million and $42 million to evYsio Medical Devices, based in Vancouver, British Columbia.
Coronary stent developer Stentys has secured the second tranche of its Series B financing from Sofinnova Partners and Scottish Equity Partners -- closing an additional $4.2 million investment from new investor Crédit Agricole Private Equity -- bringing the total B round financing to more than $22 million.
Abbott is initiating a clinical trial to study the performance of the company's new, investigational Xience Prime everolimus-eluting coronary stent system for the treatment of coronary artery disease.
Medtronic has settled all royalty disputes with Johnson & Johnson (J&J) for $270 million, which concern its licensed use of the Palmaz, Schatz and Pinchuk stent patents.
Johnson & Johnson subsidiary, Cordis, has launched a global, head-to-head, randomized clinical trial to compare its Nevo sirolimus-eluting coronary stent with the Xience V everolimus-eluting coronary stent from Abbott.
Measuring a PCI procedure by metrics such as the number or length of stents implanted may help predict the likelihood of adverse events and may also help identify which patients will benefit most from therapy with GP IIb/IIIa inhibitor eptifibatide (Integrilin ), according to the ESPIRIT randomized trial published in the February issue of Circulation: Cardiovascular Interventions.
Since 2006, the FDA has not ensured that medical devices such as cardiac defibrillators, pacemakers, replacement heart valves and coronary artery stents are being tested according to good laboratory practices (GLPs), based on a report released Feb. 18 by the independent nonprofit group the Project on Government Oversight.
Medtronic reported strong growth in profits for the medical device manufacturer's fiscal 2009 third quarter, which ended Jan. 23.
|
To better study the efficacy of the Combo Bio-engineered Sirolimus Eluting Stent, OrbusNeich has announced that a clinical trial to evaluate the success of the stent is underway in patients with symptomatic, ischemic heart disease.
From 2004 to 2008, total procedures performed in angio labs grew 20 percent, from four million in 2004 to 4.8 million procedures in 2008 for hospitals with 150 beds or more, resulting in an average annual growth rate of 4 to 5 percent, according to a report from market research firm IMV.
Interventional device developer Stentys has received CE Mark approval of its disconnectable and self-expanding stent platform for treatment of coronary artery bifurcations.
Boston Scientific has announced that President and CEO Jim Tobin will retire and that its board of directors has appointed Ray Elliott the new president and CEO, effective July 13.
Stents coated with paclitaxel (Taxus from Boston Scientific) may be a safe, effective treatment option for coronary artery disease (CAD) patients age 70 and older, and should not be withheld due to advanced patient age, according to a study reported in the June 2 issue of Circulation: Cardiovascular Interventions.
The FDA has granted Humanitarian Use Device (HUD) designation to ITGI Medical's Over and Under and Aneugraft pericardium-covered stents for treatment of perforations and dissections of native coronary arteries and saphenous vein grafts.
Interventional cardiology device developer OrbusNeich Medica has filed a lawsuit alleging patent infringement, breach of contract and misappropriation of trade secrets against Boston Scientific.
Bioabsorbable polymer drug-eluting stents are safe and effective in patients with single coronary artery lesions after two years, with no cardiac deaths, retreatment of diseased lesions or stent thromboses reported, according to the outcomes of the ABSORB trial published in the March 12 issue of the Lancet that will be presented at the American College of Cardiology (ACC) conference this month in Orlando, Fla.
Cordis, a Johnson & Johnson company, has reported that its Cypher Select Plus Sirolimus-eluting coronary stent has received CE marking within the EU for treatment of patients with diabetes.
Boston Scientific has reported its financial results for the 2008 fourth fiscal quarter and full year, which ended Dec. 31, 2008.
|
RSS 
Middle age introduces itself in many ways; one is atrial fibrillation (AF). My onset of AF seems to have coincided with a mountain bike accident in the woods of North Carolina that resulted in some cracked ribs.
The use of health IT to reduce rehospitalizations will be welcome but also disruptive, said Stephen Jencks, an independent consultant in healthcare safety during a Feb. 24 webinar on the potential use of health IT to mitigate rehospitalizations, sponsored by the Agency for Healthcare Research and Quality (AHRQ).